Cardiometabolic Disease Is an Epidemic Clinical Diagnosis of Metabolic Syndrome Adiposity Insulin Resistance Inflammation and Oxidative Stress Whats the Correlation Typical Characteristics of the Patient With MetSyn ID: 776059
Download Presentation The PPT/PDF document " Application of the Data:" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Application of the Data:
Slide2Slide3Cardiometabolic Disease Is an Epidemic
Slide4Clinical Diagnosis of Metabolic Syndrome
Slide5Adiposity, Insulin Resistance, Inflammation and Oxidative Stress - What's the Correlation?
Slide6Typical Characteristics of the Patient With MetSyn
Slide7Risk-Enhancing Factors for CVD2018 ACC/AHA Guidelines
Slide8Treating the Risk Factors
Slide9Treating the Risk Factors (cont)
Slide10Outcomes Data of CV Risk Reduction With Guideline-Indicated Therapies
Slide11Aspirin Use for the Prevention of CVD
Slide12Patient With MetSyn With Multiple Comorbidities
Slide13Who Should Be on Statin Therapy?
Slide14Team Clinician-Patient Discussion
Slide15Pearls in Management of SAMS
Slide16Typical Patient With Known CAD & SAMS
Slide17REDUCE-ITIcosapent Ethyl (EPA) vs Placebo
Slide18Lifestyle Management
Slide19Pitavastatin Meta-AnalysisNODM vs Placebo or Statin Control
Slide20Effects of Nonstatin Therapy on DM
Slide21Icosapent Ethyl Label
Slide22Risk of Developing NODMMeta-Analysis of Placebo-Controlled Statin Trials
Slide23Predisposing Factors for NODM
Slide24Muscle AE Terminology and Tips
Slide25Reasons for Increased ASCVD Risk in HIV Infection
Slide26Copenhagen Comorbidity in HIV Infection Study
Slide27Statin Therapy Considerations in Individuals Infected With HIV
Slide28Lifestyle Management Recommendations2019 AACE/ACE Consensus Statement
Slide29Common Drug Classes That May Interact With Statins
Slide30Drug-Drug InteractionsUse of Statins With Protease Inhibitors
Slide31Team-Based Multidisciplinary Approach
Slide32INTREPIDPitavastatin vs Pravastatin in ART-Treated, HIV-1-Infected Individuals With Dyslipidemia
Slide33REPRIEVE Trial Design With Pitavastatin
Slide34Conclusions
Slide35Abbreviations
Slide36Abbreviations (cont)
Slide37Abbreviations (cont)
Slide38Abbreviations (cont)